| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT05485961 Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects… |
Trial sites expanded: 542 -> 547 locations |
| 2026-06-04 | NCT07001280 A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients… |
Trial sites expanded: 18 -> 22 locations |
| 2026-06-03 | NCT05485961 Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects… |
Enrollment increased: 2310 -> 3110 participants |
| 2026-05-28 | NCT07080905 Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to <… |
Trial sites reduced: 11 -> 2 locations |
| 2026-05-15 | NCT06806657 Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-15 | NCT06806657 Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to… |
Enrollment reduced: 30 -> 18 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07619820 A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT03684018 | Two Dose Levels of Privigen in Pediatric CIDP | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Recruiting |
| NCT07076446 | An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and… | Primary Immunodeficiency | Active, Not Recruiting |
| NCT06806657 | Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to… | Hereditary Angioedema | Active, Not Recruiting |
| NCT07326592 | Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung… | Alpha1 Antitrypsin Deficiency | Not Yet Recruiting |
| Phase 3 | |||
| NCT06617897 | Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei… | Acquired Fibrinogen Deficiency | Recruiting |
| NCT06003387 | Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With… | Hemophilia B | Recruiting |
| NCT07094087 | Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult… | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | Recruiting |
| NCT07080905 | Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to <… | Hemophilia B | Recruiting |
| NCT06399289 | Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese… | Hemophilia B | Active, Not Recruiting |
| NCT06738485 | Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With… | Congenital Hemophilia A | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT05485961 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects… | Atherosclerotic Cardiovascular Disease in Patients With ESKD | Recruiting |
| Phase 2 | |||
| NCT07224360 | Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) | Sickle Cell Disease | Recruiting |
| NCT06699849 | Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle… | Sickle Cell Disease Vaso-occlusive Crisis | Recruiting |
| NCT07332091 | Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator… | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Recruiting |
| Phase 1 | |||
| NCT07619820 | A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End… | End Stage Kidney Disease (ESKD) | Not Yet Recruiting |
| Not specified | |||
| NCT06008938 | An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX®… | Hemophilia B | Recruiting |
| NCT07001280 | A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients… | Hereditary Angioedemas | Recruiting |